Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2016 | Side effects of novel drugs and managing patient expectations in CLL

Paolo Ghia • 3 Jun 2016
EHA 2016
Chronic Lymphocytic Leukemia

Paolo Ghia, MD, PhD from the San Raffaele Scientific Institute, Milan, Italy discusses the side effects of novel drugs in chronic lymphocytic leukemia (CLL). According to Dr Ghia, the toxicity profile of novel drugs is better compared to immunochemotherapy but neverthless, side effects are to be expected. Therefore, the rules to start treatment remain the same, i.e. the disease has to be progressive. In order to manage patient expectations about receiving novel drugs, it is important to inform patients about these side effects as Dr Ghia explains.
Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.

More from Paolo Ghia

1:21
Monoclonal B-cell lymphocytosis: a disease to be (or not to be)
Paolo Ghia • 7 Apr 2024
MBL: biology, classification & the possibility of early interception
Andrew Rawstron et al. • 25 Mar 2024
2:20
Monoclonal B-cell lymphocytosis: at a crossroad between disease and senescence
Paolo Ghia • 8 Dec 2023
3:00
Five-year follow-up of the CAPTIVATE trial: ibrutinib retreatment in patients with CLL
Paolo Ghia • 8 Dec 2023

Related Videos

3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
3:18
A Phase I study of JBH492, an anti-CCR7 antibody-drug conjugate, in lymphoid malignancies
Pau Abrisqueta • 5 Apr 2024
0:44
Early detection and interception across hematological cancers
Irene Ghobrial • 8 Apr 2024
1:21
Monoclonal B-cell lymphocytosis: a disease to be (or not to be)
Paolo Ghia • 7 Apr 2024
The content of VJHemOnc is intended for healthcare professionals